Activated donor immune cells may prevent severe complication after allogeneic stem cell transplantation

Дата публикации: 20-09-2026 18:00:01

Researchers have successfully conducted the first clinical trial using activated regulatory T cells (ATregs, Actileucel)—derived from white blood cells of healthy blood donors. This novel cell therapy aims to prevent graft-versus-host disease (GvHD) following an allogeneic stem cell transplant. The Phase I/II study has yielded extremely encouraging results: ATregs can be produced within 24 hours and injected immediately afterward; administration is safe and well-tolerated by patients—a significant step toward a widely available cell therapy. The research is published in Transplantation and Cellular Therapy.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Wiskott-Aldrich syndrome: Long-term results of gene therapy developed	0	13.28	24-09-2026
2	A blood-based approach could enable personalized immunotherapy without the need for a tumor biopsy	0	10.91	29-09-2026
3	Scientists find the gene that drives T-cell exhaustion, revealing new strategy to improve immune responses	0	9.6	23-09-2026
4	'Plug-and-play' CAR T technology adapts as cancer changes	0	8.18	22-09-2026
5	Newly discovered inflammatory cell signaling could open the door to autoimmune disease treatments	0	10.81	23-09-2026
6	Metabolic activity of gut bacteria can either promote or inhibit function of CAR T cells in cancer therapy	0	6.96	28-09-2026
7	New potential for Crohn’s treatment	0	7.95	11-09-2026
8	Engineered 'triple-threat' immune cells could fight plaque buildup that causes heart attacks and strokes	0	6.75	22-09-2026
9	Boosted Bacille Calmette-Guérin vaccine strategy significantly reduces tuberculosis relapse, scientists find	0	9.58	17-09-2026
10	Teaching the immune system to control HIV	0	7.4	17-09-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 8.94. Источник: medicalxpress.com.